Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Debt Repayment

Cash used to repay borrowings during the period.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Debt Repayment · Q4 FY2025 · quarter ended Dec 2025

Debt repayment of -CN¥9.86M in Q4 FY2025

Q4 FY2025 debt repayment was -CN¥9.86M.

Context

  • Debt repayment amounted to 10.4% of revenue in FY2025, up 8.9 pp from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥9.86M— QoQ
Last fiscal yearDec 2025
-CN¥12.09M+341.7% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+341.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

CNY · from the cash flow

Latest · FY2025
(12.09M) CNY
Year-over-year change
-341.7%

Debt Repayment vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +341.7% is the highest of 8, against a peer median of +0.0%.
  • Debt repayment amounts to 10.4% of revenue for ZYBT, versus a peer median of 5.6%.
ZYBT Competitors
Debt Repayment for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥12.09M CNY+341.7%—10.4%
PDEXPro-Dex, Inc.LTM Mar 2026$8.41M USD-228.6%+66.3%11.3%
TILInstil Bio, Inc.LTM Mar 2026$6.61M USD+139.4%-54.5%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$203K CAD-41.7%——
SERASera Prognostics, Inc.LTM Mar 2026$81K USD-81.9%-13.8%142.1%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$55.38K CAD+33.3%+0.9%—
APYXApyx Medical CorporationLTM Mar 2026$20K USD+0.0%-48.7%0.0%
EXOZeXoZymes, Inc.LTM Mar 2026$2.81K USD+106.5%——
SRZNSurrozen, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ZYBT) —+0.0%-13.8%5.6%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income46.47M55.74M37.51M13.47M(82.97M)
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
Deferred Income Tax(358K)(1.09M)758K924K11.1M
Stock-Based Compensation00000
Change in Working Capital(33.71M)(66.82M)(20.49M)(977K)44.83M
Accounts Receivables(40.91M)(47.38M)38.05M11.31M61.41M
Inventory(12.34M)(12.33M)(12.9M)(5.88M)6.25M
Accounts Payables17.63M(9.67M)(35.61M)(404K)(3.36M)
Other Working Capital1.91M2.56M(10.03M)(6M)(19.47M)
Other Non-Cash Items3.4M10.7M6.5M3.47M14.42M
Operating Cash Flow31.81M17.34M48.18M41.05M13.33M
Capital Expenditures(26.4M)(27.33M)(11.6M)(27.77M)(12.63M)
Acquisitions (Net)00000
Purchases of Investments00(1.22M)00
Sales of Investments00000
Other Investing Activities(7.21M)0(3.15M)(14.08M)(11.62M)
Investing Cash Flow(26.27M)(27.33M)(11.77M)(27.67M)(12.63M)
Debt Repayment8M34.88M24.97M(2.74M)(12.09M)
Common Stock Issued000043.08M
Common Stock Repurchased00000
Dividends Paid(11.05M)(21.43M)(39.45M)(16.02M)0
Other Financing Activities0(1)(4.5M)(3.37M)1.32M
Financing Cash Flow(3.05M)13.46M(18.98M)(22.13M)32.31M
Effect of Forex Changes000168K(1.29M)
Net Change in Cash2.49M3.46M17.44M(8.58M)31.73M
Free Cash Flow5.41M(9.99M)36.58M13.27M703K

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.